1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Thrombocythaemia Myelofibrosis Global Clinical Trials Review, H2, 2015

Thrombocythaemia Myelofibrosis Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, “Thrombocythaemia Myelofibrosis Global Clinical Trials Review, H2, 2015" provides an overview of Thrombocythaemia Myelofibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombocythaemia Myelofibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Thrombocythaemia Myelofibrosis Global Clinical Trials Review, H2, 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Thrombocythaemia Myelofibrosis to Hematological Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Thrombocythaemia Myelofibrosis to Hematological Disorders Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 72
Abbreviations 72
Definitions 72
Research Methodology 73
Secondary Research 73
About GlobalData 74
Contact Us 74
Disclaimer 74
Source 75

List of Tables
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials by Region, 2015* 6
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 9
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 10
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, North America, Top Countries, 2015* 11
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2015* 12
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 13
Proportion of Thrombocythaemia Myelofibrosis to Hematological Disorders Clinical Trials, G7 Countries (%), 2015* 14
Thrombocythaemia Myelofibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Thrombocythaemia Myelofibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Thrombocythaemia Myelofibrosis to Hematological Disorders Clinical Trials, E7 Countries (%), 2015* 17
Thrombocythaemia Myelofibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Thrombocythaemia Myelofibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials by Phase, 2015* 20
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 21
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Thrombocythaemia Myelofibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 25
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 28

List of Figures
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials by Region (%), 2015* 6
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 7
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 8
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 9
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 10
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 11
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2015* 12
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 13
Proportion of Thrombocythaemia Myelofibrosis to Hematological Disorders Clinical Trials, G7 Countries (%), 2015* 14
Thrombocythaemia Myelofibrosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 15
Thrombocythaemia Myelofibrosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 16
Proportion of Thrombocythaemia Myelofibrosis to Hematological Disorders Clinical Trials, E7 Countries (%), 2015* 17
Thrombocythaemia Myelofibrosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 18
Thrombocythaemia Myelofibrosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 19
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials by Phase (%), 2015* 20
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 21
Thrombocythaemia Myelofibrosis Therapeutics, Global, Clinical Trials by Trial Status, 2015* 22
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, by End Point Status, 2015* 23
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 24
Thrombocythaemia Myelofibrosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 25
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 26
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 27
Thrombocythaemia Myelofibrosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 28
GlobalData Methodology 73

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Protein Therapeutics Market 2017-2021

Global Protein Therapeutics Market 2017-2021

  • $ 3500
  • Industry report
  • December 2016
  • by Infiniti Research Limited

About Protein Therapeutics Therapeutic proteins are used to effectively treat a wide array of diseases such as protein deficiency diseases; chronic diseases such as cancer, rheumatoid arthritis (RA), ankylosing ...

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2017

Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010 to 2017

  • $ 2995
  • Industry report
  • February 2017
  • by Currentpartnering

Summary The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the co-development deals ...

Hemostasis Global Clinical Trials Review, H2, 2016

Hemostasis Global Clinical Trials Review, H2, 2016

  • $ 2500
  • Industry report
  • December 2016
  • by GlobalData

Hemostasis Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Hemostasis Global Clinical Trials Review, H2, 2016" provides an overview of Hemostasis clinical trials ...


Download Unlimited Documents from Trusted Public Sources

Blood Disease Statistics in the US - Forecast

  • March 2017
    10 pages
  • Blood Disease  

    Compression The...  

    Cardiovascular ...  

  • United States  

View report >

Blood Disease Statistics and Therapy Market in the US

  • February 2017
    45 pages
  • Blood Disease  

    Therapy  

  • United States  

View report >

Blood Disease Statistics and Therapy Market in the US

  • February 2017
    45 pages
  • Blood Disease  

    Therapy  

  • United States  

View report >

Global Therapy Market

3 months ago

Related Market Segments :

Blood Disease

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.